Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target

(MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve…